Journey Medical Corporation (DERM) Stock Forecast
DERM analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $13.75 average of analyst targets
- Upside to target
- +176.9% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $0.01
- 52-week range
- $4.39 – $9.26
DERM analyst ratings
4 analystsNumber of analysts at each rating.
DERM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DERM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.05 | $0.03 | −$0.09 | +102.8% | 4 |
| Current fiscal year (2026) | −$0.07 | −$0.20 | $0.02 | −$0.47 | +85.6% | 4 |
| Next fiscal year (2027) | $0.67 | $0.35 | $1.07 | −$0.07 | +1,096.3% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DERM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $21.4M | $19.1M | $23.8M | +21.5% | 4 |
| Current fiscal year (2026) | $80.1M | $75.1M | $85.4M | +29.4% | 4 |
| Next fiscal year (2027) | $130.1M | $110.2M | $159.0M | +62.5% | 4 |
DERM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DERM revenue: reported and forecast
DERM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.05 | $0.01 | $0.01 | $0.01 | $0.00 | −95.2% | 0 up · 0 down |
| Current fiscal year (2026) | $0.07 | −$0.04 | −$0.04 | −$0.04 | −$0.07 | −203.8% | 0 up · 0 down |
| Next fiscal year (2027) | $1.04 | $0.68 | $0.68 | $0.68 | $0.67 | −35.2% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DERM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DERM beat in 7 of 12.
What analysts expect from DERM
4 analysts cover Journey Medical; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.75, 176.9% above the latest close of $4.96. Analysts expect earnings of −$0.07 per share for 2026, +85.6% from a year earlier. For 2027 the average estimate is $0.67 per share on revenue of $130.1 million. Journey Medical beat the EPS estimate in 7 of the last 12 quarters.
Related: DERM income statement, DERM key metrics, DERM chart. See the DERM stock overview for the latest quote and news.
DERM forecast FAQ
What is Journey Medical's price target?
The average analyst price target for Journey Medical is $13.75, 176.9% above the latest close of $4.96.
Is Journey Medical a buy, hold or sell?
Of 4 analysts covering Journey Medical, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Journey Medical's EPS forecast?
Analysts forecast −$0.07 per share for 2026 (range −$0.20 to $0.02); for 2027 the estimate is $0.67.
What is Journey Medical's revenue forecast?
The average revenue estimate for 2026 is $80.1 million, growth of 29.4%; for 2027 it is $130.1 million.
When does Journey Medical report earnings?
Journey Medical is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $0.01.
Does Journey Medical usually beat earnings estimates?
Journey Medical reported EPS at or above the analyst estimate in 7 of the last 12 quarters.